Biostage Q1 net loss widens to $2.2M; settles lawsuit, raises $5.1M placement

Harvard Apparatus Regenerative Technology, Inc.

2022-Q1 EPS reported -$0.20

Q1 net loss of $2.2M ($0.20 per share) vs $0.9M loss ($0.09) in Q1 2021; G&A up $1.4M on legal costs.
Raised $5.1M via private placement on May 12, 2022 to fund clinical development of BEI.
Settled wrongful death lawsuit on April 27, 2022; total estimated costs $6.0M, $5.5M unpaid; HBIO to pay $4.0M.
Cash on hand $0.7M at March 31, 2022; after placement, cash expected to fund operations through Q1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.